Contineum Therapeutics, Inc.
CTNM
$4.76
$1.1130.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -- | -- |
| SG&A Expenses | 94.91% | 81.93% | 52.54% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.50% | 50.03% | 46.57% | -- | -- |
| Operating Income | -624.55% | -416.57% | -314.36% | -- | -- |
| Income Before Tax | -354.54% | -282.38% | -251.02% | -- | -- |
| Income Tax Expenses | -- | -- | -126.35% | -- | -- |
| Earnings from Continuing Operations | -360.53% | -285.99% | -254.34% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -360.53% | -285.99% | -254.34% | -- | -- |
| EBIT | -624.55% | -416.57% | -314.36% | -- | -- |
| EBITDA | -613.76% | -411.19% | -310.80% | -- | -- |
| EPS Basic | 0.65% | -445.15% | -246.65% | -- | -- |
| Normalized Basic EPS | -122.43% | -148.03% | -175.26% | -- | -- |
| EPS Diluted | 60.22% | -214.92% | -10.26% | -- | -- |
| Normalized Diluted EPS | -611.05% | -523.21% | -734.99% | -- | -- |
| Average Basic Shares Outstanding | 980.37% | 736.63% | 487.85% | -- | -- |
| Average Diluted Shares Outstanding | 773.76% | 575.35% | 373.69% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |